Meeting
2021 Genitourinary Cancers Symposium
Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of treatment response to novel hormones in metastatic castrate-resistant prostate cancer: Real-world data from a single institution.
Authors
Emily Scott
Royal Free Hospital, London, United Kingdom
Emily Scott , Katia Pasciuti , Magdalena Kubiak , Gillian Marks , Sarah Needleman , Kate Smith , Mark Prentice
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 52)
DOI
10.1200/JCO.2021.39.6_suppl.52
Abstract #
52
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2023 ASCO Genitourinary Cancers Symposium
Effect of early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting on cancer-specific survival in metastatic castrate-resistant prostate cancer.
First Author: Kelly Lehner
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri